Marksans Pharma jumps 33 per cent in a month on strong delivery buying

Marksans Pharma has continued its up-move ever since the drug maker got a nod from USFDA for its loratadine liquid filled capsules 10 mg. The stock has outperformed the broad market index by increasing more than 33 per cent in terms of returns generated.

The approval holds importance as it was the very same Goa plant which got UK health regulators restricted GMP (good manufacturing practices) certificate which led to changing of company's fortune and therefore making the stock face all the brunt when it corrected by more than 50 per cent in a week.

As company has got a nod from the same plant, it marks an important event in the growth trajectory for the company from here on, which has reflected in the price movement of Marksans Pharma stock.

It has been an out performer amongst the overall Pharma pack. For the coming future we are certain that the worst may be behind for Marksans Pharma in terms of regulatory troubles and the company should move ahead with its generic filing in the period ahead.

Shares of Marksans Pharma were trading at Rs 57.15 at the time of writing this report.